Central and Eastern Europe Fund's Glen increased its holdings in Haisco and Pharmaron in the third quarter, but strong performance still fails to prevent net redemptions
On October 28th, Gran disclosed the third-quarter report for 2025 for the funds under management. In terms of stock positions, the stock position of China Europe Medical Health reached a historical high, rising to 94.56%. In terms of performance, during the third quarter, all three funds managed by Gran significantly outperformed the performance benchmark for the same period. Among them, China Europe Mingrui New Starting Point made nearly 60% profit in the third quarter. However, it is worth noting that all three funds continued to experience net redemptions, with China Europe Medical Health and China Europe Medical Innovation facing the highest redemption amounts since their inception. (The Paper)